Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.

Effects of Low Dose Aspirin and Low Molecular Weight Heparin Cotreatment, Alone and/or in Combination on Implantation and Clinical Pregnancy Rates in Repeated Implantation Failures in IVF Cycle.

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01924104

Enrollment

400

Registered

2013-08-16

Start date

2013-08-31

Completion date

2014-12-31

Last updated

2013-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come

Keywords

IVF failure, implantation rate, heparin & aspirin

Brief summary

The purpose of the study is to determine whether low-dose aspirin and low molecular weight heparin improve the implantation and pregnancy rates in patients with repeated implantation failures in IVF cycle.

Detailed description

The investigators hypothesize that cotreatment of low dose aspirin & low molecular weight heparin may improve implantation & clinical pregnancy rates.

Interventions

DRUGLow molecular weight heparin

2500 mIU/day, subcutaneously

DRUGLow dose aspirin

75 mg/day, orally

DRUGHeparin & aspirin

Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)

OTHERNaCl

Equivalent volume of NaCl 0.9%, subcutaneously

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Aged between 19 to 35 years; * Basal follicle-stimulating hormone (FSH) levels of ≤8 IU/l * Body mass index (BMI) between 19 kg/m2 and 25 kg/m2 * Presence of both ovaries; ≥2 previous IVF failures * Good quality embryos for transfer * Endometrial thickness between 10 mm and 14 mm

Exclusion criteria

* Polycystic ovary syndrome * Endometriosis

Design outcomes

Primary

Measure	Time frame
Biological pregnancy test	14 days

Secondary

Measure	Time frame
Fetal heart/Gestational sac	8 weeks

Countries

India

Contacts

Primary ContactVandana Bansal, MS DGO PhD

bansal.drvandana@gmail.com+91-0532-2417252

Backup ContactAshwani K Bansal, MS

arpitivf@gmail.com+91-0532-2417252

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026